儿童成熟B细胞非霍奇金淋巴瘤LMB方案治疗后的远期健康结局
该研究基于儿童肿瘤幸存者研究,比较了接受LMB方案(n=126)与非LMB方案(n=444)治疗的成熟B细胞非霍奇金淋巴瘤幸存者及 siblings(n=1029)的远期健康结局。LMB幸存者相比兄弟姐妹有更多不良健康结局,但与 非LMB幸存者相比,除神经系统毒性(如癫痫、平衡问题、震颤等)风险显著升高外,整体慢性健康状况、健康状态、神经认知及社会经济结局无显著差异。
要点
- LMB幸存者相比兄弟姐妹不良健康结局风险增加
- LMB与非LMB幸存者整体慢性健康状况无显著差异
- LMB幸存者癫痫、平衡问题、震颤等神经系统疾病风险显著高于非LMB幸存者
核心结论
- LMB与非LMB方案幸存者远期健康结局总体相当,但LMB幸存者神经毒性风险增加。
研究设计与样本
- 多变量回归模型比较LMB方案幸存者(n=126)、非LMB方案幸存者(n=444)和兄弟姐妹(n=1029)的慢性健康状况、健康状态及社会经济和神经认知结局。
主要发现
- LMB幸存者诊断时中位年龄10.2岁(范围2.5-20.5岁),评估时中位年龄24.0岁(范围10.3-35.3岁)。
- 与非LMB幸存者相比,LMB幸存者癫痫风险RR 15.2(95%CI 3.1-73.4),平衡问题RR 8.9(95%CI 2.3-34.8),震颤RR 7.5(95%CI 1.9-29.9),腿部无力RR 8.1(95%CI 2.5-26.4),严重头痛RR 3.2(95%CI 1.6-6.3),持续手臂、腿或背痛RR 4.0(95%CI 2.2-7.1)。
- LMB C组风险组幸存者(n=50)上述神经系统疾病风险最高;但除功能状态较差(OR 2.7,95%CI 1.2-5.8)外,其他不良健康状态或社会经济结局风险未增加。
临床怎么用
- LMB方案幸存者需关注神经系统毒性(癫痫、平衡问题、震颤、无力、头痛、疼痛)的长期监测。
- LMB C组风险组幸存者功能状态较差风险较高,应予以关注。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The widely used, risk-based Lymphome Malin de Burkitt (LMB) chemotherapy regimen has improved survival rates for children with mature B-cell non-Hodgkin lymphoma (NHL); however, associated late effects remain understudied. We assessed late health outcomes after LMB treatment in the Childhood Cancer Survivor Study. PATIENTS AND METHODS: Multivariable regression models compared chronic health conditions, health status, and socioeconomic and neurocognitive outcomes between survivors of NHL treated with the LMB regimen (n = 126), survivors of NHL treated with non-LMB regimens (n = 444), and siblings (n = 1,029). RESULTS: LMB survivors were a median age of 10.2 years (range, 2.5 to 20.5 years) at diagnosis and 24.0 years (range, 10.3 to 35.3 years) at evaluation. Compared with siblings, LMB survivors were at increased risk for adverse health outcomes. However, survivors of NHL treated with LMB and non-LMB regimens did not differ with regard to risk of having any chronic health conditions, impaired health status, neurocognitive deficits, or poorer socioeconomic outcomes. Increased risk for the following specific neurologic conditions was observed in LMB survivors compared with non-LMB survivors: epilepsy (relative risk [RR], 15.2; 95% CI, 3.1 to 73.4); balance problems (RR, 8.9; 95% CI, 2.3 to 34.8); tremors (RR, 7.5; 95% CI, 1.9 to 29.9); weakness in legs (RR, 8.1; 95% CI, 2.5 to 26.4); severe headaches (RR, 3.2; 95% CI, 1.6 to 6.3); and prolonged arm, leg, or back pain (RR, 4.0; 95% CI, 2.2 to 7.1). The survivors from the group C LMB risk group (n = 50) were at the highest risk for these conditions; however, except for worse functional status (odds ratio, 2.7; 95% CI, 1.2 to 5.8), they were not at increased risk for other adverse health status or socioeconomic outcomes compared with non-LMB survivors. CONCLUSION: Survivors treated with LMB and non-LMB regimens are largely comparable in late health outcomes except for excess neurotoxicity among LMB survivors. These data inform treatment efforts seeking to optimize disease control while minimizing toxicity.
引用
- Ehrhardt MJ, Chen Y, Sandlund JT, et al. Late Health Outcomes After Contemporary Lymphome Malin de Burkitt Therapy for Mature B-Cell Non-Hodgkin Lymphoma: A Report From the Childhood Cancer Survivor Study. J Clin Oncol. 2019. PMID: 31283408. doi:10.1200/JCO.19.00525
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。